Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect ...

Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.

A major breakthrough for RSV research was the discovery of a conformational change of the fusion (F) protein following the establishment of infection. The RSV F protein is a trimer in two ...

Learn to recognize dangerous RSV symptoms in children beyond typical cold signs, including breathing changes, distinctive ...

When little Eva Valdimarsdottir was just 14-months-old she was hospitalised with a severe and “very scary” case of RSV, but ...

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...

RESVIA ®is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 /Moderna, Inc.

Specifically Cormier studies that lasting impacts and immune response of Respiratory Syncytial Virus. RSV is an infection of the lungs that is responsible for the hospitalization of 58,000 to ...